Apixaban Gains Indication for DVT Prophylaxis After Knee and Hip Replacement — Physician’s First Watch
Apixaban Gains Indication for DVT Prophylaxis After Knee and Hip Replacement
By Larry Husten
The FDA has approved the anticoagulant apixaban (Eliquis) for the prophylaxis of deep vein thrombosis (DVT) in patients who have undergone hip or knee replacement surgery. The new indication joins the previously approved indication of stroke prevention in patients who have nonvalvular atrial fibrillation.
The DVT indication is based on results of the ADVANCE clinical trial program in which apixaban was compared with enoxaparin in more than 11,000 patients (see background links below).
Adapted from CardioExchange